Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy

被引：1
|
作者：
Mafong, DD [1 ]
Lee, GA
Yu, S
Tien, P
Mauro, T
Grunfeld, C
机构：
[1] San Francisco Dept Vet Affairs Med Ctr, Metab & Endocrine Sect, San Francisco, CA USA
[2] San Francisco Dept Vet Affairs Med Ctr, Serv Dermatol, San Francisco, CA USA
[3] San Francisco Dept Vet Affairs Med Ctr, Infect Dis Sect, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
[6] Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA
来源：
AIDS | 2004年 / 18卷 / 12期
关键词：
D O I：
10.1097/01.aids.0000131387.38103.7e
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1742 / 1744
页数：3
相关论文
共 50 条
  • [21] Hyaluronic acid new formulation: Experience in HIV-associated facial lipoatrophy
    Bechara, Falk G.
    Gambichler, Thilo
    Brockmeyer, Norbert H.
    Sand, Michael
    Altmeyer, Peter
    Hoffmann, Klaus
    [J]. DERMATOLOGY, 2008, 217 (03) : 244 - 249
  • [22] Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy
    Kim, Roy J.
    Carlow, Dean C.
    Rutstein, Jessica H.
    Rutstein, Richard M.
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2007, 20 (01): : 65 - 74
  • [23] Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy
    Massella, M.
    Ivanovic, J.
    Bellagamba, R.
    De Vita, R.
    Fracasso, L.
    Tozzi, V.
    Fragola, V.
    Rizzica, M.
    Narciso, P.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 223 - 228
  • [24] Infectious complications of Bio-Alcamid™ soft tissue endoprosthesis treatment of HIV-associated facial lipoatrophy
    Nadarajah, J.
    Collins, M.
    Loutfy, M.
    Walmsley, S.
    [J]. ANTIVIRAL THERAPY, 2010, 15 : A22 - A23
  • [25] Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy
    Loutfy, Mona R.
    Brunetta, Jason
    Kovacs, Colin
    Diong, Christina
    Gamble, Molly
    Antoniou, Tony
    Smith, Graham
    Halpenny, Roberta
    Rosenes, Ron
    Raboud, Janet M.
    [J]. HIV CLINICAL TRIALS, 2011, 12 (06): : 323 - 332
  • [26] Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy
    Burgess, CM
    Quiroga, RM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) : 233 - 239
  • [27] Safety and efficacy of New-Fill® (Polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF)
    Engelhard, P
    Knies, M
    [J]. XIV INTERNATIONAL AIDS CONFERENCE: CLINICAL SCIENCES AND CARE, 2002, : 365 - 367
  • [28] Deciphering the molecular mechanisms involved in HIV-associated lipoatrophy by transcriptomics: a pilot study
    Perez-Matute, Patricia
    Iniguez, Maria
    Recio-Fernandez, Emma
    Oteo, Jose-Antonio
    [J]. JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2016, 73 (03) : 431 - 443
  • [29] Absence of benefit on body composition with rosiglitazone or pravastatin but short term improvement of visceral adiposity with growth hormone in persons with HIV-associated lipoatrophy (HALS)
    Macallan, D. C.
    Mandalia, S.
    Panayiotakopoulos, G.
    Pandol-Kaljevic, V.
    Baldwin, C.
    Moyle, G. J.
    [J]. ANTIVIRAL THERAPY, 2006, 11 (07) : L53 - L53
  • [30] Treatment of HIV-associated nephropathy
    Sothinathan, R
    Briggs, WA
    Eustace, JA
    [J]. AIDS PATIENT CARE AND STDS, 2001, 15 (07) : 363 - 371
12345